Matthew Haustein, MD
Cardiovascular Disease · Jonesboro, ARNPI 1154545309
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,400 of the $7,915 with a category attached, or 68.2%. 30 manufacturers reported payments, led by Abbott at 50.0% of the total.
Across 321 payments — averaging $24.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Medtronic$1K
- Novartis$704
- Pfizer$228
- Edwards Lifesciences$216
- Amgen$202
- plus $1K from 24 others
What the payments were for
- Travel & lodging$2,39830%
- Food & beverage$5,40068%
- Education$1171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 56 | $3,960 |
| Medtronic(2 entities) | 100 | $1,200 |
| Novartis | 45 | $704 |
| Pfizer | 15 | $228 |
| Edwards Lifesciences | 2 | $216 |
| Amgen | 13 | $202 |
| Boehringer Ingelheim | 11 | $169 |
| Boston Scientific | 7 | $165 |
| Chiesi USA, Inc. | 25 | $117 |
| AstraZeneca | 3 | $112 |
| Sanofi-aventis U.S. LLC | 5 | $101 |
| Johnson & Johnson | 5 | $81 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $77 |
| Inspire Medical Systems, Inc. | 2 | $62 |
| Penumbra, Inc. | 3 | $51 |
| Biotronik Inc. | 3 | $51 |
| E.r. Squibb & Sons, L.L.C. | 3 | $47 |
| Novo Nordisk | 2 | $43 |
| Shockwave Medical, Inc | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Cardiva Medical, Inc. | 2 | $36 |
| Cordis US CORP. | 1 | $35 |
| Cvrx, Inc. | 1 | $30 |
| Angiodynamics, Inc. | 1 | $27 |
| Avinger Inc. | 1 | $25 |
| Abiomed | 1 | $24 |
| Stryker | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Terumo Medical Corporation | 1 | $17 |
| Atricure, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$2,283
- SAPIEN 3 Ultra RESILIA$148
- MitraClip System$132
- Ultreon$128
- Mitra Clip system$124
- MitraClip$100
How this compares
$7,915 in reported general payments places this provider in the 70th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 307 | $235,455 |
| XareltoRivaroxaban | 138 | $98,972 |
| EntrestoSacubitril/Valsartan | 67 | $49,509 |
| BrilintaTicagrelor | 84 | $38,520 |
| JardianceEmpagliflozin | 34 | $33,340 |
| MultaqDronedarone Hcl | 21 | $29,839 |
| Repatha SureclickEvolocumab | 32 | $25,154 |
| FarxigaDapagliflozin Propanediol | 27 | $15,138 |
| Praluent PenAlirocumab | 20 | $14,327 |
| Flecainide Acetate | 203 | $5,757 |
| Ranolazine ErRanolazine | 54 | $3,412 |
| Prasugrel Hcl | 44 | $2,202 |
| SotalolSotalol Hcl | 186 | $2,140 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 12 | $2,075 |
| Propafenone Hcl | 15 | $1,927 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $228 | $235,455307 claims |
| Johnson & JohnsonXarelto | $81 | $98,972138 claims |
| AstraZenecaBrilinta, Farxiga | $112 | $53,658111 claims |
| NovartisEntresto | $704 | $49,50967 claims |
| Boehringer IngelheimJardiance | $169 | $33,34034 claims |
| Sanofi-aventis U.S. LLCMultaq | $101 | $29,83921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Jonesboro
- Barry TedderJonesboro$130K
- Maximiliano ArroyoJonesboro$46K
- Dharmendra PatelJonesboro$36K
- Nephertiti EfeovbokhanJonesboro$15K
- Anthony WhiteJonesboro$8K
- Jaime ChavezJonesboro$7K
- Mahesh AradhyaJonesboro$5K
- Michael IsaacsonJonesboro$5K
- Ian CawichLittle Rock$294K
- Harvinder DodEl Dorado$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.